BACKGROUND: @entity17852 and its intravenous prodrug @entity14340 are reported to increase @entity1031 risk after coronary artery bypass grafting. The authors conducted a randomized trial to examine their safety and analgesic efficacy in @entity1 recovering from major noncardiac surgical procedures. METHODS: The trial was randomized and double-blind, with 10 days of treatment and 30 days of follow-up. @entity1 (n = 1,062) received either parenteral @entity14340 for 3 days and oral @entity17852 for the rest of the treatment period or placebo medications throughout. The frequency of predefined adjudicated postrandomization adverse events, including cardiovascular @entity1031 , @entity8 , gastroduodenal ulceration, and wound-healing complications, was assessed in each group. Secondary efficacy endpoints included @entity1 ' @entity158 ratings, opioid analgesic consumption (recorded as @entity1286 equivalents), and reports of opioid-related adverse effects. RESULTS: Predefined adjudicated adverse events had similar frequencies among @entity1 who received @entity14340 and @entity17852 (2.7%) and placebo @entity1 (3.2%) (P = 0.58), including cardiovascular @entity1031 events (1.0% in each group; P = 1.0). Placebo @entity1 consumed more @entity1286 equivalents (66.2 +/- 92.4 mg) than did @entity1 receiving @entity14340 and @entity17852 (43.2 +/- 65.7 mg) (P < 0.001). Placebo @entity1 had higher mean @entity158 ratings on each of study days 2-10 (P < 0.01) and reported more opioid-related symptom distress on days 2-6 (P < 0.01). CONCLUSIONS: @entity14340 and @entity17852 are useful adjuncts to opioids for the treatment of @entity282 in noncardiac surgical @entity1 . Further study will be required to determine the safety profile of @entity14340 and @entity17852 administered to @entity1 with known @entity731 after noncardiac surgery.

Safety and efficacy of the cyclooxygenase-2 inhibitors XXXX and @entity17852 after noncardiac surgery.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction'] @entity17852 :: ('MESH:C406224', 'Chemical') :: ['valdecoxib', 'Valdecoxib'] @entity14340 :: ('MESH:C409945', 'Chemical') :: ['Parecoxib', 'parecoxib'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism', 'thromboembolic'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic disease'] @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']
@entity14340 :: (MESH:C409945,Chemical) :: ['parecoxib']
